- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 02.01. | J&J's Rybrevant/Lazcluze combination approved by EC for EGFR-mutated lung cancer | ||
| 02.01. | Merck's Winrevair granted MHRA approval to treat pulmonary arterial hypertension | ||
| 23.12.24 | Pfizer's Braftovi regimen receives FDA accelerated approval to treat colorectal cancer | ||
| 23.12.24 | AstraZeneca's Tagrisso granted EC approval in EGFR-mutated lung cancer | ||
| 23.12.24 | Launching a novel drug treatment in Japan | ||
| 23.12.24 | The importance of caregivers in the patient journey | ||
| 20.12.24 | Novo Nordisk invests $1.2bn to establish rare disease production facility in Denmark | ||
| 20.12.24 | Gilead's seladelpar recommended by CHMP to treat primary biliary cholangitis | ||
| 20.12.24 | Taking the campaign against cancer into the cloud | ||
| 20.12.24 | Shaping tomorrow with strategic foresight in early commercialisation | ||
| 20.12.24 | Brand strategy - reviewing what you've learnt | ||
| 19.12.24 | Merck gains rights to Hansoh's preclinical GLP-1 candidate in deal worth $2bn | ||
| 19.12.24 | Amgen's Blincyto granted MHRA approval for new acute lymphoblastic leukaemia indication | ||
| 19.12.24 | FDA approves Organon's Vtama cream to treat atopic dermatitis in adults and children | ||
| 19.12.24 | Rare vs common diseases: key differences in educational approaches | ||
| 19.12.24 | Communicating AI in healthcare: a guide for effective strategy | ||
| 19.12.24 | Big hats, no cattle | ||
| 18.12.24 | AbbVie to expand immunology pipeline with $200m Nimble Therapeutics acquisition | ||
| 18.12.24 | GSK's Jemperli receives positive CHMP opinion for expanded endometrial cancer use | ||
| 18.12.24 | Eli Lilly's Omvoh recommended by CHMP to treat Crohn's disease in adults | ||
| 18.12.24 | Is omnichannel right for rare diseases? | ||
| 18.12.24 | Creating a future with more clinical empathy | ||
| 17.12.24 | Sanofi's tolebrutinib granted FDA breakthrough designation for MS | ||
| 17.12.24 | CHMP recommends Galderma's nemolizumab for atopic dermatitis and prurigo nodularis | ||
| 17.12.24 | The need for a human touch in an AI world |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
